FDA Refuse to File: The 60-Day Gate Before Review Begins

Within 60 days of receiving a new drug application, FDA must decide whether the submission is complete enough to review at all — a refuse-to-file (RTF) decision under 21 CFR 314.101(d) for NDAs and 21 CFR 601.2(a) for BLAs. Teams that treat the 60-day window as a formality — a box-check before the real review starts — are the ones most likely to receive the letter. RTF is not a judgment on your science. It is FDA declining to judge your science at all, because the application never cleared the threshold that lets a reviewer start.

A completeness test, not a scientific one

The filing decision and the approval decision answer different questions. Filing asks whether the application, on its face, contains what section 505(b) requires for an NDA or the parallel biologics provisions require for a BLA — the right forms, the right components, in the right form. Approval asks whether the evidence supports the claim. FDA can refuse to file an application built on a sound development program if the submission itself is missing pieces, and it can file an application that later draws a Complete Response Letter once reviewers work through the data. Conflating the two is the single most common strategic error: sponsors who spend their pre-submission energy on the scientific narrative and treat the completeness checklist as clerical are the ones surprised by an RTF letter for a candidate that might otherwise have been approvable.

Where applications actually get refused

FDA's stated bases for refusing to file are procedural and structural, not scientific — which is exactly why they are preventable with enough lead time:

• CMC completeness gaps. Missing or insufficient chemistry, manufacturing, and controls information — stability data, batch records, or facility detail — needed to support a substantive review.
• Procedural and form deficiencies. An incomplete application form, electronic submission (eCTD) non-conformance, or an inadequate patent certification.
• Late amendments. Components the sponsor agreed at a pre-submission meeting to supply, not delivered within 30 calendar days of the original submission.
• Translation gaps. Portions of the application not in English, submitted without a complete and accurate English translation.

A refuse-to-file letter tells a sponsor about a fatal completeness gap in 60 days. A full review cycle would have told them the same thing, months later and at far greater cost. Why the 60-day gate exists

The informal conference most sponsors don't use

If FDA review staff flag a potential completeness concern during the 60-day window, a sponsor can request an informal conference with the review division to address it before the agency reaches a decision. This is the one structured opportunity to close a gap before the clock runs out, and it is routinely left unused by teams who treat the window as read-only — something to wait out rather than something to work. CBER runs the equivalent process for biologics filed under §601.2(a). Waiting silently for a letter, when a fixable gap could have been raised and resolved during the window itself, converts a preventable delay into a mandatory one.

None of this requires guessing at FDA's scientific judgment before it has been rendered. It requires treating the filing decision as its own gate, with its own criteria, worked on its own timeline — separately from the case for approval a Complete Response Letter might eventually test. Companies that run a genuine filing-readiness review against §314.101(d) or §601.2(a) before submission are the ones who spend their 60-day window waiting for a filing decision, not fighting to avoid a refusal.